CNTX net incomeQ2 2026-$14.56M
CNTX net income was -$14.56M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.83M a year earlier. For the full fiscal 2025 it was -$36.12M, compared with -$26.73M in fiscal 2024.
Context Therapeutics Inc. (CNTX) financials
For the twelve months ended Jun 30, 2026, Context Therapeutics Inc. reported -$45.96M of net income.
- Net income, TTM
- -$45.96M
- Free cash flow, TTM
- -$34.03M
- EPS, diluted, TTM
- -$0.48
- Cash
- $42.99M
- Market cap
- $18.7M
FY2020FY2025
FY2021FY2025
CNTX revenue and earnings growth
CNTX EPSQ2 2026-$0.15
CNTX diluted EPS was -$0.15 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.09 a year earlier. For the full fiscal 2025 it was -$0.38.
CNTX free cash flowQ2 2026-$7.04M
CNTX free cash flow was -$7.04M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$5.84M a year earlier. For the full fiscal 2025 it was -$26.42M, compared with -$14.56M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Research and development | $31.86M | $22.70M | $17.78M | $7.09M | $3.81M | $1.64M |
| Selling, general and admin | $7.85M | $7.22M | $7.29M | $7.79M | $3.63M | $930.7K |
| Operating income | -$39.70M | -$29.92M | -$25.07M | -$15.38M | -$10.53M | -$2.57M |
| Interest expense | - | - | - | - | $64.2K | $661.2K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$36.12M | -$26.73M | -$23.96M | -$14.84M | -$10.46M | $6.64M |
| EPS, basic | -$0.38 | -$0.46 | -$1.50 | -$0.93 | -$3.69 | $3.07 |
| EPS, diluted | -$0.38 | -$0.46 | -$1.50 | -$0.93 | -$3.69 | -$3.96 |
| Diluted shares | 95.2M | 58.4M | 16.0M | 16.0M | 2.8M | 2.1M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $66.00M | $94.43M | $14.45M | $35.50M | $49.69M | $341.0K |
| Current assets | $68.35M | $97.90M | $16.05M | $37.85M | $51.26M | $299.3K |
| Total assets | $68.49M | $98.13M | $16.06M | $37.97M | $51.31M | $467.3K |
| Current liabilities | $8.02M | $2.75M | $4.19M | $3.21M | $3.03M | $9.55M |
| Total liabilities | $8.02M | $2.86M | $4.19M | $3.21M | $3.03M | $9.62M |
| Shareholders' equity | $60.47M | $95.27M | $11.87M | $34.76M | $48.27M | -$16.92M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$26.39M | -$14.56M | -$21.05M | -$13.55M | -$8.80M | -$1.03M |
| Capital expenditures | $33.9K | $7.3K | $0 | $36.8K | $0 | - |
| Free cash flow | -$26.42M | -$14.56M | -$21.05M | -$13.59M | -$8.80M | - |
| Investing cash flow | -$2.03M | -$14.76M | $0 | -$536.8K | -$250.0K | $0 |
| Financing cash flow | -$15.3K | $109.29M | $0 | -$102.1K | $58.39M | $1.15M |
| Stock-based compensation | $1.33M | $841.9K | $1.08M | $976.4K | $511.1K | $219.2K |
| Depreciation and amortization | $16.3K | $10.9K | $12.0K | $9.3K | $0 | - |
Key ratios
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $12.53M | $7.02M | $11.84M | $8.72M | $7.83M | $3.46M | $2.52M | $16.83M | $1.38M | $1.97M | $5.30M | $4.49M |
| Selling, general and admin | $2.44M | $2.33M | $1.96M | $1.89M | $1.93M | $2.07M | $1.79M | $1.88M | $1.70M | $1.85M | $1.63M | $1.70M |
| Operating income | -$14.97M | -$9.34M | -$13.80M | -$10.61M | -$9.76M | -$5.53M | -$4.31M | -$18.70M | -$3.09M | -$3.82M | -$6.93M | -$6.18M |
| Net income | -$14.56M | -$8.68M | -$13.03M | -$9.69M | -$8.83M | -$4.58M | -$3.34M | -$17.46M | -$2.25M | -$3.67M | -$6.77M | -$5.87M |
| EPS, basic | -$0.15 | -$0.09 | -$0.14 | -$0.10 | -$0.09 | -$0.05 | - | -$0.22 | -$0.04 | -$0.23 | -$0.42 | -$0.37 |
| EPS, diluted | -$0.15 | -$0.09 | -$0.14 | -$0.10 | -$0.09 | -$0.05 | - | -$0.22 | -$0.04 | -$0.23 | -$0.42 | -$0.37 |
| Diluted shares | 95.2M | 95.2M | - | 95.2M | 95.2M | 95.2M | - | 80.5M | 55.0M | 16.0M | - | 16.0M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $42.99M | $54.53M | $66.00M | $76.94M | $83.52M | $89.35M | $94.43M | $84.80M | $101.54M | $10.09M | $14.45M | $21.68M |
| Current assets | $45.82M | $58.52M | $68.35M | $79.06M | $86.95M | $92.73M | $97.90M | $86.07M | $102.70M | $11.04M | $16.05M | $22.97M |
| Total assets | $46.13M | $58.86M | $68.49M | $79.23M | $87.15M | $92.97M | $98.13M | $86.33M | $102.71M | $11.05M | $16.06M | $22.99M |
| Current liabilities | $7.88M | $6.53M | $8.02M | $6.04M | $4.56M | $1.90M | $2.75M | $2.33M | $1.60M | $2.61M | $4.19M | $4.60M |
| Total liabilities | $7.96M | $6.66M | $8.02M | $6.06M | $4.61M | $1.98M | $2.86M | $2.47M | $1.60M | $2.61M | $4.19M | $4.60M |
| Shareholders' equity | $38.17M | $52.20M | $60.47M | $73.17M | $82.54M | $90.98M | $95.27M | $83.86M | $101.10M | $8.44M | $11.87M | $18.38M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.02M | -$11.43M | -$8.94M | -$6.58M | -$5.84M | -$5.03M | -$4.91M | -$1.93M | -$3.36M | -$4.36M | -$7.23M | -$3.46M |
| Capital expenditures | $18.5K | $37.3K | $0 | $0 | $0 | $33.9K | $0 | $7.3K | $0 | $0 | $0 | $0 |
| Free cash flow | -$7.04M | -$11.47M | -$8.94M | -$6.58M | -$5.84M | -$5.06M | -$4.91M | -$1.94M | -$3.36M | -$4.36M | -$7.23M | -$3.46M |
| Investing cash flow | -$4.52M | -$37.3K | -$2.00M | $0 | $0 | -$33.9K | $0 | -$14.76M | $0 | $0 | $0 | $0 |
| Financing cash flow | $0 | $0 | $0 | $0 | $0 | -$15.3K | $14.54M | -$44.6K | $94.80M | $0 | $0 | $0 |
| Stock-based compensation | $528.1K | $409.2K | $325.2K | $323.1K | $389.1K | $293.7K | $231.8K | $213.0K | $157.0K | $240.0K | $256.1K | $254.9K |
| Depreciation and amortization | $6.6K | $4.7K | $4.1K | $4.1K | $4.1K | $4.1K | $2.9K | $2.8K | $2.6K | $2.6K | $2.6K | $3.1K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.81 | 8.96 | 8.52 | 13.10 | 19.09 | 48.80 | 35.62 | 36.91 | 64.01 | 4.23 | 3.83 | 4.99 |
Source: XBRL data Context Therapeutics Inc. files with the SEC, latest filing dated Aug 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
CNTX peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| CNTX | - | - | -$45.96M | - | $18.7M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
CNTX FAQ
6 questionsIs CNTX profitable?
No. Context Therapeutics Inc. reported a net loss of $45.96M for the twelve months ended Jun 30, 2026.How much cash and debt does CNTX have?
Context Therapeutics Inc. reported $42.99M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is CNTX free cash flow?
Context Therapeutics Inc. generated -$34.03M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$33.97M less capital expenditures.What is CNTX earnings per share?
Diluted earnings per share were -$0.48 for the twelve months ended Jun 30, 2026, from SEC filings, restated for any stock split those filings show.When did CNTX last report financial results?
The latest statements here come from Context Therapeutics Inc.'s 10-Q filed on Aug 5, 2026, covering the period ended Jun 30, 2026.Where does this CNTX financial data come from?
Quantisnow builds these statements from the structured XBRL data Context Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.